Establishment and characterization of primary lung cancer cell lines from Chinese population

Acta Pharmacologica Sinica

Volumn 32, Issue 3, 2011, Pages 385-392

  Zheng, Chao ^a   Sun, Yi Hua ^b   Ye, Xiao Lei ^a   Chen, Hai Quan ^b   Ji, Hong Bin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

epidermal growth factor receptor; lung cancer; non small cell lung carcinomas; primary cell lines; small cell lung carcinomas

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORPHOLOGY; CARCINOGENICITY; CHINESE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPATHOLOGY; ETHNIC DIFFERENCE; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; KARYOTYPING; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; POINT MUTATION; PRIMARY TUMOR; PROTEIN DOMAIN;

ADENOCARCINOMA; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79952403534     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.214     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 2010; 102: 1310-21.
4. Masters JR. HeLa cells 50 years on: the good, the bad and the ugly Nat Rev Cancer 2002; 2: 315-9. (Pubitemid 37336517)
5. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976; 17: 62-70
6. Masuda N, Fukuoka M, Takada M, Kudoh S, Kusunoki Y. Establish-ment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defned medium (ACL-4). Chest 1991; 100: 429-38
7. Loh PM, Clamon GH, Robinson RA, White ML, Hukku B, Rossi NP, et al. Establishment and characterization of four new human non-smal cell lung cancer cell lines. Cancer Res 1984; 44: 3561-9 (Pubitemid 14098612)
8. Anger B, Bockman R, Andreeff M, Erlandson R, Jhanwar S, Kameya T, et al. Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma. Cancer 1982; 50 1518-29. (Pubitemid 12034546)
9. Baillie-Johnson H, Twentyman PR, Fox NE, Walls GA, Workman P, Watson JV, et al. Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer 1985; 52: 495-504 (Pubitemid 16221570)
10. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identifcation of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45 2913-23 (Pubitemid 15232769)
11. Simms E, Gazdar AF, Abrams PG, Minna JD. Growth of human smal cell (oat cell) carcinoma of the lung in serum-free growth factor-supple mented medium. Cancer Res 1980; 40: 4356-63
12. Oie HK, Russell EK, Carney DN, Gazdar AF Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cel Biochem Suppl 1996; 24: 24-31.
13. Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer 2010; 68: 309-18.
14. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS muta-tions in patients with adenocarcinoma of the lung. Korean J Intern Med 2009; 24: 48-54
15. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-68
16. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201-5.
17. Sun YH, Fang R, Gao B, Han XK, Zhang JH, Pao W, et al. Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin 2010; 31: 647-8
18. Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, et al. Spectrum of LKB1 EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol 2010; 5: 1130-5.
19. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemo-therapy. Expert Opin Drug Metab Toxicol 2009; 5: 243-57
20. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differencesn lung cancer therapy. Br J Cancer 2008; 99: 1757-62
21. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, et al. Lung adenocarcinoma from east asian never smokers is a disease largely defned bytarge-table oncogenic mutant kinases. J Clin Oncol 2010; 28: 4616-20
22. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Bio 2005; 70: 419-26 (Pubitemid 44124897)
23. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008; 60: S23-30
24. Gazdar AF, Oie HK. Cell culture methods for human lung cancer Cancer Genet Cytogenet 1986; 19: 5-10. (Pubitemid 16149765)
25. Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD. Growth of cel ines and clinical specimens of human non-small cell lung cancer in a serum-free defned medium. Cancer Res 1986; 46: 798-806 (Pubitemid 16145440)
26. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and geftinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55 (Pubitemid 40812628)
27. Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, Sarkar FH Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epiderma growth factor receptor leads to greater anti-tumor activity in pan-creatic cancer. J Cell Biochem 2010; 110: 171-81.
28. Sugaya M, Takenoyama M, Osaki T, Yasuda M, Nagashima A, Sugio K, et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002; 122: 282-8 (Pubitemid 34754175)
29. NCI-Navy Medical Oncology Branch cell line supplement. J Cel Biochem Suppl 1996; 24: 1-291.
30. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-smal cell lung cancer, and loci clustering. Cancer Res 2000; 60: 4894-906
31. Lam DC, Girard L, Suen WS, Chung LP, Tin VP, Lam WK, et al. Establishment and expression profling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. J Thorac Onco 2006; 1: 932-42 (Pubitemid 47181359)
32. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-82 (Pubitemid 41161259)
33. Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, et al. Geftinib (IRESSA) sensitive lung cancer cell lines show phosphoryla-tion of Akt without ligand stimulation. BMC Cancer 2006; 6: 277
34. Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009; 124: 1778-84
35. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H et al. Somatic mutations of the HER2 kinase domain in lung adeno-carcinomas. Cancer Res 2005; 65: 1642-6 (Pubitemid 40478587)
36. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008; 68: 5827-38
37. Lu Y, Liang K, Li X, Fan Z. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1 alpha. Mol Cancer 2007; 6: 63
38. Sordella R, Bell DW, Haber DA, Settleman J. Geftinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7. (Pubitemid 39100331)
39. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64: 7241-4 (Pubitemid 39372059)